Navigation Links
Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
Date:1/9/2008

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to NPS Pharmaceuticals on its recently-completed partnering of Gattex(TM) (teduglutide) with Nycomed. Under the terms of the agreement, NPS has licensed rights to Gattex outside North America to Nycomed for the treatment of gastrointestinal disorders.

Gattex is a GLP-2 analog in development for the treatment of short-bowel syndrome (SBS). SBS can result from one or more bowel surgeries related to inflammatory bowel disease or injury. In a recent Phase III trial, patients in the low dose Gattex group showed a statistically significant reduction in parenteral nutrition vs. placebo, while the high dose group showed a trend in the difference between the treatment group and placebo, but this did not reach statistical significance. NPS is also pursuing development of Gattex as a possible treatment for chemotherapy-induced gastrointestinal mucositis in cancer patients and necrotizing enterocolitis in preterm infants.

Under the terms of the agreement, NPS and Nycomed will share future development costs 50:50. NPS maintains commercialization rights for the product in the US, Canada, and Mexico.

The agreement includes an upfront payment to NPS of $35 million, and combined development and sales milestones that could potentially total more than $150 million in additional payments from Nycomed. Royalties to NPS for sales in Nycomed's territories, although not publicly disclosed, are in the double-digit range.

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:

-- Mergers & Acquisitions

-- Strategic Partnering from preclinical research to product development

and commercialization

-- Spin-Outs and Divestitures

-- Financing (Private Placements)

-- Advisory Services to define the role of transactions in achieving

strategic objectives

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. The company's 60 person scientific and business team, supported by its 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life sciences companies and management, provide Burrill with unparalleled access and insight.

Burrill is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports including: The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. In association with the California Healthcare Institute, Burrill publishes The Journal of Life Sciences -- a bimonthly magazine. Burrill's flagship publication is its annual "State of the Industry" report, the most recent 21st Edition being Biotech 2007: Life Sciences -- A Global Transformation. The 22nd Edition is entitled Biotech 2008: Life Sciences -- A 20/20 Vision to 2020, available 1Q '08. These publications provide the latest insight, intelligence and information on the life sciences industry.

http://www.burrillandco.com.


'/>"/>
SOURCE Burrill Merchant Banking
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Burrill & Company Announces Promotions
2. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
3. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
8. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
11. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by ... the state’s 76 fastest-growing private companies; a small percentage of the state's 615,000+ small ... on the percent change in revenue from 2012 to 2015. , As ...
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast Inc., developers of an ... across the globe, today announced the availability of a Zika virus antibody from ... treatment and prevention measures for the Zika virus, the virus’s geographical distribution continues ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas P. ... in The Woodlands, Texas , now ... percent of treated fat cells in just 25-minutes, leaving ... to 90 percent of Americans report feeling bothered by ... fat reduction procedures are a growing industry. This innovative ...
(Date:5/2/2016)... 2016 Q BioMed Inc. (QBIO), ... Mannin Research Inc. will be attending the Association for ... from May 1-5, 2016 in Seattle Washington ... its vendors and research partners. The meeting provides organizations ... other collaborative opportunities for the MAN-01 program for treatment ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
Breaking Biology News(10 mins):